Business
Sareum Half-Year Report
Sareum Half-Year Report.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n\nSareum Holdings PLC \n(\"Sareum\" or the \"Company\")\nHalf-Year Report for the Six Months Ended 31 December 2024\nCambridge, UK, 25 March 2025 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces its unaudited results for the six months ended 31 December 2024.\nSareum also provides a broader update on its operational activities and pipeline progress.\nOPERATIONAL HIGHLIGHTS - INCLUDING POST-PERIOD UPDATES\nSDC-1801 (autoimmune disease)\nSDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.\n· Successfully completed Phase 1 clinical trial for SDC-1801 with single ascending dose (\"SAD\"), multiple ascending dose (\"MAD\") and food effect studies.\n· SDC-1801 achieved blood plasma levels significantly exceeding predicted therapeutic exposure with a half-life of 17-20 hours, confirming the potential for once-daily dosing. Significant dose-responsive biomarker effects were observed.\n· No deaths or serious adverse events due to SDC-1801 were reported, with frequency of adverse events (all mild or moderate) similar in active and placebo groups.\n· The Clinical Study Report was received in December 2024.\n· Strengthened intellectual property position with:\no US Patent and Trademark Office granted a patent (US Patent No. 12,187,716) on SDC-1801's chemical structure, its use in treating inflammatory diseases, and certain methods of chemical synthesis.\no Patent allowance in China protecting certain crystalline forms of SDC-1801 and methods of their preparation with a similar Decision to Grant that was recently received from the Japanese Patent Office.\nSRA737 (cancer)\nSRA737 is a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.\n· After the period end, Sareum successfully acquired the licence for SRA737 following the termination of a licensing agreement between CRT Pioneer Fund (\"CPF\") and a US-based licensee in December 2024.\n· Sareum renegotiated significantly improved e...